Transition from Heparin to DOAC for Pulmonary Embolism
For most patients with pulmonary embolism, you can transition from heparin to a DOAC immediately or within 0-2 hours, depending on which DOAC you choose. Rivaroxaban and apixaban do not require any heparin lead-in and can be started directly, while dabigatran and edoxaban require 5-10 days of parenteral anticoagulation before initiation 1.
Timing of Transition by DOAC Type
Immediate Transition (No Heparin Lead-in Required)
- Rivaroxaban: Start 15 mg twice daily with food for 21 days, then 20 mg once daily 1, 2
- Apixaban: Start 10 mg twice daily for 7 days, then 5 mg twice daily 1, 2
For patients on IV heparin, stop the infusion immediately when giving the first DOAC dose. For intermittent heparin, give the DOAC 0-2 hours before the next scheduled heparin dose 3.
Requires 5-10 Days Heparin Lead-in
- Dabigatran: Give 150 mg twice daily only after 5-10 days of parenteral anticoagulation 1
- Edoxaban: Give 60 mg once daily only after at least 5-10 days of parenteral anticoagulation 1
Recent research suggests 3-5 days of LMWH lead-in may be optimal for non-high-risk PE when transitioning to DOACs that require parenteral lead-in 4. This intermediate duration (versus <3 days or >5 days) was associated with lower mortality and composite adverse outcomes without increasing bleeding risk.
Duration of DOAC Therapy
Provoked PE (Transient Risk Factor)
- 3 months of anticoagulation 5
- Examples: surgery, trauma, immobilization, pregnancy, oral contraceptives
- Stop after 3 months if the risk factor no longer exists 5
Unprovoked PE (No Identifiable Trigger)
- Indefinite therapy if low-to-moderate bleeding risk 1, 5
- 3 months if high bleeding risk 1
- After 6 months of initial therapy, consider dose reduction:
Recurrent Unprovoked PE
- Indefinite therapy if low-to-moderate bleeding risk 1
- Reassess bleeding risk and treatment benefit at least annually 1
Cancer-Associated PE
- Indefinite therapy as long as cancer is active 1, 5
- DOACs are now preferred over LMWH based on recent trials (HOKUSAI VTE-Cancer, SELECT-D, Caravaggio) 1
- Caution: Patients with GI or GU malignancies may have higher bleeding risk with DOACs compared to LMWH 1
Key Dosing Details
Initial Treatment Phase (First 3-6 Months):
- Rivaroxaban: 15 mg BID × 21 days → 20 mg daily
- Apixaban: 10 mg BID × 7 days → 5 mg BID
- Dabigatran: 150 mg BID (after heparin lead-in)
- Edoxaban: 60 mg daily (after heparin lead-in)
Extended Treatment Phase (After 6 Months):
- Rivaroxaban: Can reduce to 10 mg daily 1
- Apixaban: Can reduce to 2.5 mg BID 1
- Dabigatran and edoxaban: Continue same dose
Important Caveats
DOACs are contraindicated in:
- Severe renal impairment (CrCl <30 mL/min for rivaroxaban, dabigatran, edoxaban; <25 mL/min for apixaban) 1, 6
- Antiphospholipid antibody syndrome (use VKA instead) 6, 7
- Pregnancy or lactation 6
Prefer LMWH or VKA over DOACs when:
- Significant drug-drug interactions with P-glycoprotein or CYP3A4 inhibitors/inducers 7
- Bariatric surgery or malabsorption conditions 7
- Extreme body weights 7
The 2021 ACC guidelines and 2020 ESC guidelines both strongly recommend DOACs over VKAs for non-cancer VTE 1, 6, and the 2020 ASH guidelines give a conditional recommendation for DOACs over VKAs based on reduced bleeding risk 7.